Two CD95 tumor classes with different sensitivities to antitumor drugs
暂无分享,去创建一个
Alicia Algeciras-Schimnich | M. Peter | E. Pietras | S. Holbeck | Patrick Legembre | A. Algeciras-Schimnich | B. Barnhart | Susan L Holbeck | Eric M Pietras | Bryan C Barnhart | Patrick Legembre | Shrijay Vijayan | Marcus E Peter | S. Vijayan
[1] J. Blenis,et al. FADD is required for multiple signaling events downstream of the receptor Fas. , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[2] M. Boyd,et al. Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. , 1992, Anticancer research.
[3] P. Möller,et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. , 1989, Science.
[4] E. Nabel,et al. Extracellular matrix interacts with soluble CD95L: Retention and enhancement of cytotoxicity , 2001, Nature Immunology.
[5] M. Peter,et al. APO-1 (CD95)-dependent and -independent antigen receptor-induced apoptosis in human T and B cell lines. , 1995, International immunology.
[6] Masato Tanaka,et al. Expression of the functional soluble form of human fas ligand in activated lymphocytes. , 1995, The EMBO journal.
[7] D A Scudiero,et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. , 1989, Journal of the National Cancer Institute.
[8] Alicia Algeciras-Schimnich,et al. Molecular Ordering of the Initial Signaling Events of CD95 , 2002, Molecular and Cellular Biology.
[9] M. Peter,et al. The CD95(APO-1/Fas) DISC and beyond , 2003, Cell Death and Differentiation.
[10] M. Peter,et al. The CD95 type I/type II model. , 2003, Seminars in immunology.
[11] M. Peter,et al. The two CD95 apoptosis signaling pathways may be a way of cells to respond to different amounts and/or forms of CD95 ligand produced in different tissues , 2000, Cell Death and Differentiation.
[12] P. Möller,et al. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. , 1992, Journal of immunology.
[13] M. Hung,et al. Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. , 2002, Molecular cell.
[14] Henning Walczak,et al. TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL , 1997, The EMBO journal.
[15] S. Nagata,et al. Downregulation of Fas ligand by shedding , 1998, Nature Medicine.
[16] J. Blenis,et al. Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade , 1998, Current Biology.
[17] A. Strasser,et al. Bcl-2 does not inhibit cell death induced by the physiological Fas ligand: implications for the existence of type I and type II cells , 2000, Cell Death and Differentiation.
[18] Christian A. Rees,et al. Systematic variation in gene expression patterns in human cancer cell lines , 2000, Nature Genetics.
[19] H. Düssmann,et al. Apoptosis induced by disruption of the actin cytoskeleton is mediated via activation of CD95 (Fas/APO-1) , 2002, Cell Death and Differentiation.
[20] Ingo Schmitz,et al. Differential Modulation of Apoptosis Sensitivity in CD95 Type I and Type II Cells* , 1999, The Journal of Biological Chemistry.
[21] A. Algeciras-Schimnich,et al. Actin dependent CD95 internalization is specific for Type I cells , 2003, FEBS letters.
[22] J. Rossant,et al. FGF signaling regulates mesoderm cell fate specification and morphogenetic movement at the primitive streak. , 2001, Developmental cell.
[23] B. Boyer,et al. Induction and regulation of epithelial-mesenchymal transitions. , 2000, Biochemical pharmacology.
[24] M. Peter,et al. Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.
[25] H. Moses,et al. Phosphatidylinositol 3-Kinase Function Is Required for Transforming Growth Factor β-mediated Epithelial to Mesenchymal Transition and Cell Migration* , 2000, The Journal of Biological Chemistry.
[26] J. Tschopp,et al. Conversion of Membrane-bound Fas(CD95) Ligand to Its Soluble Form Is Associated with Downregulation of Its Proapoptotic Activity and Loss of Liver Toxicity , 1998, The Journal of experimental medicine.